MENUMENU
  • Covid Clear
  • About Us

        • About Us

          An industry leading services provider in viral challenge studies and laboratory services supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.

          • More about hVIVO
        • Overview
        • Executive Leadership Team
        • Scientific Papers / Abstracts
        • Quality Commitment
        • Ethics & Compliance
        • FluCamp
        • Human Challenge Programme
        • Challenge Agent Consortium
        • PrEP Biopharm Ltd
        • Imutex Ltd.
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
          • Disease in Motion®
  • News, Media & Events

        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

        • News & Media
        • Media Coverage
        • Company News
        • Media Press Kit
        • Videos
        • Events
        • img

          LATEST PRESS RELEASE

          14.07.21 Directors’ Dealings

        • UPCOMING EVENTS

          Events to be announced

  • Volunteers
  • Careers
  • Contact Us

Press Announcements > FDA approves first seasonal influenza vaccine containing an adjuvant

November 26, 2015 1:32 pm
Follow @hVIVO_UK

Comments are closed here.

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2021 Copyright hVIVO Services Limited. All rights reserved. hVIVO Services Limited (“hVIVO”) is registered in England and Wales with registration number 02326557 and registered office at Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX, UK.
Privacy Policy | Cookie Policy